Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Akari Therapeutics Plc/ 10-Q

Quarterly Report · 10-Q

Akari Therapeutics Plc

Quarterly Report

Filed Aug 13, 2026Accepted Aug 13, 2026, 4:00 PM EDTCIK 1541157Accession 0001493152-26-037730
View company →Permanent SEC source ↗
Share

Company context

We are an oncology company developing next-generation antibody-drug conjugates, or ADCs, designed around novel proprietary cancer-killing toxins, or payloads. We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development.

Current securities

AKTXNASDAQ · ADR · Current

Recent company filings

  1. S-8 filingOct 30, 2026
  2. Submission of Matters to a Vote of Security HoldersOct 30, 2026
  3. 4 filingOct 16, 2026
  4. DEF 14A filingOct 1, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 1, 2026

Registered securities in this filing

Akari Therapeutics, Plc · 10-Q · Filed 2026-08-13

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

American Depositary Shares, each representing 80,000 Ordinary Shares, par value $0.000000005 per share

Symbol
AKTX
Exchange
NASDAQ
Classification
ADS
Status
Current
Filing context

Context: From2026-01-012026-06-30_custom_AmericanDepositarySharesEachRepresenting80000OrdinarySharesParValue0.000000005PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Ordinary Shares, $0.000000005 par value per share*

Symbol
AKTX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: From2026-01-012026-06-30_custom_OrdinaryShares0.000000005ParValuePerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000149315226037730 · 2 registered-security cover members

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.